

Ministry of Health

OHIP, Pharmaceuticals and Devices Division

Drug Submission Status

Report for May 2022

Complete Streamlined Multiple-Source

Submissions for Off-Formulary Interchangeability

The Ministry of Health and Long-Term Care has received complete submissions for the following streamlined multiple-source drug products for Off-Formulary Interchangeability (OFI) designation. Subject to confirmation of Drug Identification Numbers (DIN) and prices by the manufacturers, as well as review and approval by the Executive Officer, these products may be designated as OFI drugs in a future Formulary update. Final OFI designation status will be communicated when the Formulary update is published on the Ministry website and via a OPDD Notice.

Manufacturer	Product	Reference Product	Generic Name	Strength	Dosage Form	DIN
Auro Pharma Inc.	Auro-Ondansetron Injection	Zofran	ONDANSETRON HYDROCHLORIDE DIHYDRATE	4 mg/ 2 mL	IV solution	02491524
Auro Pharma Inc.	Auro-Ondansetron Injection	Zofran	ONDANSETRON HYDROCHLORIDE DIHYDRATE	8mg/ 2mL	IV solution	02491532
Sanis Health Inc.	Pramipexole	Mirapex	PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE	0.5mg	tablet	02367610